Subtype
Lip and Oral Cavity Carcinoma
CI-CAN-00003027Explore in graph →
96 active trials2 evidence items
- NCIt
- C9315
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003027Explore in graph →
Clinical trials
320 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (40)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03121313 | Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+ | unknown | Phase 2 | 68 | Chang Gung Memorial HospitalOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT01316757 | Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer | completed | Phase 2 | 24 | Fox Chase Cancer CenterOTHER | 1 | Feb 26, 2018 | clinicaltrials |
| NCT02068157 | Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer | terminated | Phase 2 | 3 | Roswell Park Cancer InstituteOTHER | 1 | Oct 11, 2017 | clinicaltrials |
| NCT01542931 | TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma | completed | Phase 2 / Phase 3 | 256 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 21, 2017 | clinicaltrials |
| NCT02196168 | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | May 3, 2017 | clinicaltrials |
| NCT00095563 | Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2017 | clinicaltrials |
| NCT01267240 | Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 2 | Apr 14, 2017 | clinicaltrials |
| NCT01256385 | Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy(MAESTRO HN) | completed | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 2 | Mar 27, 2017 | clinicaltrials |
| NCT00095628 | SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2017 | clinicaltrials |
| NCT02331875 | Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity | terminated | Phase 1 / Phase 2 | 3 | Innate PharmaINDUSTRY | 2 | Jan 4, 2017 | clinicaltrials |
| NCT02985255 | Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue | unknown | Phase 2 | 30 | HealthCare Global Enterprise Ltd.INDUSTRY | 1 | Dec 7, 2016 | clinicaltrials |
| NCT02960724 | uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer | unknown | Phase 2 | 90 | Rigshospitalet, DenmarkOTHER | 1 | Nov 10, 2016 | clinicaltrials |
| NCT02007200 | Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Oct 24, 2016 | clinicaltrials |
| NCT01108042 | TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer | completed | Phase 1 / Phase 2 | 71 | Orlando Guntinas-Lichius, Prof. Dr. med.OTHER | 1 | May 18, 2016 | clinicaltrials |
| NCT02119728 | Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT02739204 | Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma | unknown | Phase 2 | 270 | China Medical University HospitalOTHER | 1 | Apr 15, 2016 | clinicaltrials |
| NCT01192204 | Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention | completed | Phase 1 / Phase 2 | 41 | Ohio State UniversityOTHER | 1 | Aug 14, 2015 | clinicaltrials |
| NCT00458978 | Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | May 5, 2015 | clinicaltrials |
| NCT00114283 | Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00507767 | Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 1, 2014 | clinicaltrials |
| NCT00101348 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00103259 | Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 71 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00492089 | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00513435 | Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2014 | clinicaltrials |
| NCT00780312 | Physiotherapy Treatment for Patients Suffering From Head and Neck Cancer(HOHF) | completed | Phase 2 | 97 | Rigshospitalet, DenmarkOTHER | 1 | Jul 2, 2013 | clinicaltrials |
| NCT01674374 | Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 0 | May 15, 2013 | clinicaltrials |
| NCT00096512 | S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00033618 | Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck | completed | Phase 2 | 144 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00077428 | Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Feb 12, 2019source: clinicaltrials